Evidence map›Paper›PMID 41854852›Full record

ReviewMolecular biology reports2026

The Dual Roles of TIMP-1 in Cancer: From Protease Inhibition to Cytokine Signaling.

Haixia Li, Xinzhou Deng, Fang Wang, Yanlin Niu, Pengfei Ruan, Li Gong, Ming Luo, Zhiguo Luo, Nan Cao

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Haixia Li *Department of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Xinzhou Deng *Department of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Fang Wang *Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Yanlin NiuDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Pengfei RuanDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Li GongDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Ming LuoDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. heavry1985@163.com.
Zhiguo LuoDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. zhiguo_luo@126.com.
Nan CaoDepartment of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. 2017203030011@whu.edu.cn.

Funding

Faculty Development Grants from Hubei University of Medicine 2023QDJZR07Hubei Province Central Nervous System Repair and Functional Reconstruction Clinical Medical Research Center Open Topic Fund 2025SJZX003Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer Open Topic Fund 2025LCOF06Natural Science Foundation of Hubei Province 2024AFB335Natural Science Foundation of Hubei Province 2024AFB352
6 · The paper itself

Abstract

Tissue inhibitor of metalloproteinase-1 (TIMP-1) has emerged as a significant focus in cancer research due to its dual functionality as both an inhibitor of matrix metalloproteinases and a multifunctional cytokine. Recent studies underscore the pivotal role of TIMP-1 in extracellular matrix remodeling, a process essential for tumor progression and metastasis. Moreover, TIMP-1 performs a variety of functions within the tumor microenvironment that extend beyond its traditional protease-inhibitory role, highlighting its importance in modulating cellular processes such as proliferation, apoptosis, and immune responses. Additionally, TIMP-1 has garnered increasing attention as a prognostic biomarker and a potential therapeutic target in oncology. This review systematically compiles recent advancements in the understanding of TIMP-1's dual functions in cancer, elucidates its mechanistic roles as both a metalloproteinase inhibitor and a cytokine-like factor, and integrates its emerging significance as a biomarker and therapeutic target across diverse cancer types. By synthesizing recent findings, this study seeks to provide novel insights into the translational potential of TIMP-1 in cancer treatment, while examining its prospective implications for therapeutic strategies and clinical interventions.

Indexed as

CytokinesNeoplasmsTissue Inhibitor of Metalloproteinase-1AnimalsBiomarkers, TumorHumansMatrix MetalloproteinasesSignal TransductionTumor MicroenvironmentBiomarkers, TumorCytokinesMatrix MetalloproteinasesTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1CancerCytokineMatrix metalloproteinase inhibitorTIMP-1Tumor microenvironment

Identifiers

PMID41854852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.